Neuroendocrine Tumor Sites

Where do neuroendocrine tumors (NETs) occur?

NETs form in specialized cells called neuroendocrine cells, which receive messages from the nervous system and then release hormones into the bloodstream. When a neuroendocrine cell  divides uncontrollably, without stopping, it can form tumors, which can then become cancerous.

Primary sites for neuroendocrine tumors

NETs can occur throughout the body, but most commonly form in the:

What if a neuroendocrine tumor spreads to other sites?

NETs can spread, or metastasize, to other locations in the body, such as the lymph nodes or the liver. When a tumor spreads it is called metastasis and may also be called advanced or malignant (cancerous). Your doctor will give your cancer a stage, which describes how far it has spread throughout the body, in terms of distance from the primary site.

Play Video

Why does neuroendocrine tumor site matter?

See why NET patients and physicians say it is important to find a NET specialist

The latest in NET News

NETRF Awards Six Grants

NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.

Get Involved

Support NET Research The Neuroendocrine Tumor Research Foundation (NETRF) is the leading funder of neuroendocrine

1 in 4

NETS occurs in the lungs.3

1 in 2

NET patients are misdiagnosed with another condition, such as irritable bowel syndrome, gastritis, or anxiety.13

< half

 Of those with NETs felt they had enough information at diagnosis.13

Search for NET specialists

Find NET doctors, treatment programs, and support groups near you

Get connected.
Follow us on social media.

3Sackstein PE, O’Neil DS, Neugut AI, et al. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Seminars in Oncol. 2018;4(13):249-258..

13National Cancer Institute. Pheochromocytoma and paraganglioma treatment (PDQ®)-patient version. 2017. Accessed October 23, 2018.